Duopharma Biotech Bhd - Asset Resilience Ratio

Latest as of December 2025: 20.08%

Duopharma Biotech Bhd (7148) has an Asset Resilience Ratio of 20.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

RM290.87 Million
≈ $73.03 Million USD Cash + Short-term Investments

Total Assets

RM1.45 Billion
≈ $363.62 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Duopharma Biotech Bhd's Asset Resilience Ratio has changed over time. Check Duopharma Biotech Bhd (7148) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Duopharma Biotech Bhd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 7148 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents RM290.87 Million 20.08%
Short-term Investments RM0.00 0%
Total Liquid Assets RM290.87 Million 20.08%

Asset Resilience Insights

  • Good Liquidity Position: Duopharma Biotech Bhd maintains a healthy 20.08% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Duopharma Biotech Bhd Industry Peers by Asset Resilience Ratio

Compare Duopharma Biotech Bhd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.62%
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
Drug Manufacturers - Specialty & Generic 6.76%
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
Drug Manufacturers - Specialty & Generic 28.06%
Neuland Laboratories Limited
NSE:NEULANDLAB
Drug Manufacturers - Specialty & Generic 9.65%
Alembic Pharmaceuticals Limited
NSE:APLLTD
Drug Manufacturers - Specialty & Generic 0.14%

Annual Asset Resilience Ratio for Duopharma Biotech Bhd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Duopharma Biotech Bhd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 11.71% RM161.25 Million
≈ $40.48 Million
RM1.38 Billion
≈ $345.72 Million
-12.35pp
2023-12-31 24.06% RM323.59 Million
≈ $81.24 Million
RM1.35 Billion
≈ $337.72 Million
+17.71pp
2022-12-31 6.34% RM77.49 Million
≈ $19.46 Million
RM1.22 Billion
≈ $306.78 Million
+3.73pp
2021-12-31 2.62% RM30.45 Million
≈ $7.64 Million
RM1.16 Billion
≈ $292.27 Million
-2.37pp
2020-12-31 4.99% RM52.81 Million
≈ $13.26 Million
RM1.06 Billion
≈ $265.74 Million
+0.46pp
2019-12-31 4.53% RM41.67 Million
≈ $10.46 Million
RM919.80 Million
≈ $230.93 Million
+1.94pp
2018-12-31 2.59% RM21.70 Million
≈ $5.45 Million
RM836.38 Million
≈ $209.99 Million
-4.33pp
2017-12-31 6.93% RM48.86 Million
≈ $12.27 Million
RM705.24 Million
≈ $177.06 Million
-5.84pp
2016-12-31 12.77% RM84.48 Million
≈ $21.21 Million
RM661.46 Million
≈ $166.07 Million
--
pp = percentage points

About Duopharma Biotech Bhd

KLSE:7148 Malaysia Drug Manufacturers - Specialty & Generic
Market Cap
$294.64 Million
RM1.17 Billion MYR
Market Cap Rank
#14701 Global
#176 in Malaysia
Share Price
RM1.22
Change (1 day)
-0.81%
52-Week Range
RM1.19 - RM1.55
All Time High
RM2.86
About

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more